Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) FCF Margin (2022 - 2025)

Historic FCF Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 1.77%.

  • Arcutis Biotherapeutics' FCF Margin rose 760600.0% to 1.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.46%, marking a year-over-year increase of 1105200.0%. This contributed to the annual value of 57.14% for FY2024, which is 3580600.0% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' FCF Margin is 1.77%, which was up 760600.0% from 0.3% recorded in Q2 2025.
  • Arcutis Biotherapeutics' FCF Margin's 5-year high stood at 0.3% during Q2 2025, with a 5-year trough of 9338.07% in Q3 2022.
  • For the 4-year period, Arcutis Biotherapeutics' FCF Margin averaged around 1293.9%, with its median value being 146.21% (2024).
  • In the last 5 years, Arcutis Biotherapeutics' FCF Margin soared by 91912400bps in 2023 and then skyrocketed by 166900bps in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' FCF Margin (Quarter) stood at 2404.19% in 2022, then surged by 83bps to 415.87% in 2023, then soared by 100bps to 1.05% in 2024, then crashed by -69bps to 1.77% in 2025.
  • Its FCF Margin was 1.77% in Q3 2025, compared to 0.3% in Q2 2025 and 47.06% in Q1 2025.